10839 results for 'ICAM-1'

Quick Facts About VolagidemabWhat is Volagidemab?Volagidemab is a glucagon-like peptide-1 (GLP-1) receptor antagonist designed to regulate glucose metabolism and energy homeostasis.How D

CD155 is read by four different receptors, and only one of them turns the killing programme on. The nectin and nectin-like ligands induced on stressed and transformed cells are simultaneously an acti

Research Pulse · Data study Where biology is heading: what PubMed and 300,000 researcher visits reveal We compared five years of PubMed publication counts with two years of researcher visits to Assa

Cancer immunotherapy has revolutionized the treatment landscape for various malignancies. One of the most promising therapeutic strategies is the use of immune checkpoint inhibitors, part

Cancer immunotherapy has revolutionized oncology, offering powerful new ways to treat various malignancies by harnessing the body's own immune system. Central to this success are immune checkpoint inh

PD-1 does not switch a T cell off; it moves the threshold. Engagement of PD-1 by PD-L1 recruits a single phosphatase into the immunological synapse, and that one recruitment event is enough to collap

Anti-angiogenic therapy does not work by starving tumours, and the trials that assumed it did are the reason the field spent a decade disappointed. Cutting off the blood supply was the original pitch

Tocilizumab reverses cytokine release syndrome within hours, and it never touches the cell that started it. That sentence contains the whole mechanism. The trigger is a T cell — engaged by a CAR, a b

Introduction to PD-1, PD-L1, and PD-L2 in Cancer ImmunotherapyThe PD-1/PD-L1 immune checkpoint pathway has been instrumental in cancer immunotherapy, with PD-1 (programmed death-1) inhibi

PD-1 gets the attention, but it is one brake among many — and the others do not work the same way. The co-inhibitory receptors are routinely drawn as interchangeable stop signs on a T cell. They are

Transplant rejection is the fastest, most violent adaptive immune response a body can mount — and it is a response to a molecule rather than to a pathogen. Somewhere between one and ten per cent of a

The neutrophil is the most heavily armed short-lived cell in the body. It leaves the marrow with its weapons already made — granules preloaded with elastase, myeloperoxidase and defensins — and spend